Drugs / SGR-1505
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05544019 | Apr 2023 → Nov 2027 expected | ALK-positive large B-cell lymphoma, B-cell chronic lymphocytic leukemia, Burkitt lymphoma, MALT lymphoma +13 | Schrödinger, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-06-27 | Schrödinger, Inc. | Regulatory Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia schrodinger.com ↗ |
| 2025-06-12 | Schrödinger, Inc. | Results Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress schrodinger.com ↗
SGR-1505 was observed to be safe, well tolerated, and clinically active, with responses observed in multiple histologies, including in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM). |
| 2023-12-14 | Schrödinger, Inc. | Results Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event schrodinger.com ↗
During Pipeline Day, Schrödinger is presenting new data showing that its novel MALT1 inhibitor, SGR-1505, was well tolerated in a Phase 1 study of 73 healthy volunteers. |
| 2023-12-10 | Schrödinger, Inc. | Results Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting schrodinger.com ↗
Schrödinger also reported preliminary pharmacodynamic data from the Phase 1 study of SGR-1505 in healthy subjects, which showed that SGR-1505 inhibited cytokine release in human whole blood and demonstrated evidence of MALT1 inhibition in humans. |
| 2022-06-28 | Schrödinger, Inc. | Regulatory Schrödinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor schrodinger.com ↗
Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for its MALT1 inhibitor, SGR-1505. |
All press releases naming this drug 8 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGR-1505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05544019 ↗ |
| Action | Inhibit | “inhibitor of MALT1” NCT05544019 ↗ |
| Modality | Small molecule | — CHEMBL6068524 ↗ |
| Route | Oral | “SGR-1505 will be administered orally.” NCT05544019 ↗ |
| Target | MALT1 | “inhibitor of MALT1” NCT05544019 ↗ |